Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections
This article was originally published in The Gold Sheet
Executive Summary
As Asian drug regulatory authorities gain confidence in their ability to regulate new drug products, they are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe.
You may also be interested in...
ICH Enhances Regulators’ Roles While Preserving Industry Access
The International Conference on Harmonization strengthens the hand of regulatory authorities in consensus-based discussions with industry, while applauding the growing role of non-ICH authorities in its expert working groups.
BRIC Nations Slow to Join PIC/S Inspection Coordination Effort
PIC/S could play an even greater role in coordinating drug GMP inspections if its members included inspectorates of all the major drug exporting nations. While India appears to lack interest, Japan, China and others have been working to qualify for membership.
‘Global Allegiance’ of Inspectorates Emerging
Drug regulatory agencies around the world are beginning to coordinate their inspection processes, which could reduce global drug manufacturers’ burden of hosting multiple GMP inspections.Some are piloting joint inspections, with a pilot for active pharmaceutical ingredient manufacturers concluding next month, and a second for drug product manufacturers under way.